InMode Ltd. Share Price Deutsche Boerse AG

Equities

154

IL0011595993

Advanced Medical Equipment & Technology

Market Closed - Deutsche Boerse AG 14:42:48 01/07/2024 BST 5-day change 1st Jan Change
17.14 EUR +3.72% Intraday chart for InMode Ltd. +2.02% -16.28%

Financials

Sales 2024 * 480M 447M 38B Sales 2025 * 520M 485M 41.18B Capitalization 1.51B 1.41B 120B
Net income 2024 * 167M 156M 13.22B Net income 2025 * 190M 177M 15.04B EV / Sales 2024 * 1.13 x
Net cash position 2024 * 968M 902M 76.59B Net cash position 2025 * 1.19B 1.11B 93.99B EV / Sales 2025 * 0.62 x
P/E ratio 2024 *
9.24 x
P/E ratio 2025 *
8.17 x
Employees 581
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.31%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.72%
1 week+2.02%
Current month+3.72%
1 month-1.97%
3 months-11.71%
6 months-16.28%
Current year-16.28%
More quotes
1 week
16.06
Extreme 16.06
17.15
1 month
16.06
Extreme 16.06
17.53
Current year
15.86
Extreme 15.86
24.76
1 year
15.86
Extreme 15.86
41.52
3 years
15.86
Extreme 15.86
41.52
5 years
15.86
Extreme 15.86
41.52
10 years
15.86
Extreme 15.86
41.52
More quotes
Managers TitleAgeSince
Founder 57 01/01/08
Chief Executive Officer 71 01/01/08
Director of Finance/CFO 46 31/12/16
Members of the board TitleAgeSince
Director/Board Member 89 06/08/19
Chief Executive Officer 71 01/01/08
Founder 57 01/01/08
More insiders
Date Price Change Volume
01/07/24 17.14 +3.72% 150
28/06/24 16.53 +2.93% 0
27/06/24 16.06 -3.54% 0
26/06/24 16.65 0.00% 0
25/06/24 16.65 -0.92% 0

Delayed Quote Deutsche Boerse AG, July 01, 2024 at 02:42 pm

More quotes
Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
17.87 USD
Average target price
25.6 USD
Spread / Average Target
+43.26%
Consensus